A study has recently been completed that compared the ease of administration or voluntary acceptance by dogs of the Luoda liquid formulation of pimobendan compared with the currently marketed commercial alternative, which are chewable tablets. 10 dogs were dosed with the liquid product and 10 with the chewable tablets twice a day for 5 days followed by a rest for 2 days then each group was switched to the other treatment for 5 days. In total, 20 dogs received 10 treatments of each product,for a total of 200 doses.The results were even more pronounced than anticipated. The voluntary acceptance rate of the chewable tablets (the registered product sold worldwide) was 49% while the voluntary acceptance rate of the Luoda product was 94.5% – a clear and substantial difference that should ensure owners can more easily and reliably improve the signs of heart disease in their dogs.
